Francesca Gabriele 1 , Matteo Foschi 1 , Andrea Morotti 2 , Federico De Santis 1 , Leondino Mammarella 3 , Silvia Ricci 4 , Federica DE Santis 4 , Berardino Orlandi 4 , Raffaele Ornello 1 , Simona Sacco 1 1 Department of Biotechnological and Applied Clinical Sciences, University of LAquila, L'Aquila, Italy, 2 Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy, 3 Operative Unit Information Flow Management and Health Statistics Service, Local Health Board 1 (LHB1) of Avezzano-Sulmona-LAquila, L'Aquila, Italy, 4 Department of Neurology and Stroke Unit, S.S
Studies suggest that its effectiveness can be as high as the results achieved through Vitamin IV treatments
PlushCare offers Rybelsus (oral semaglutide) as its clearest oral option
Orforglipron (Eli Lilly) is a non-peptide small molecule that targets the GLP-1 receptor as a single target and is taken as a once-daily tablet with no food or water restriction